In this guide
In January 2026, researchers at the University of Oxford published a study in The BMJ that reframed one of the biggest open questions in modern weight management: what actually happens when you stop taking a GLP-1 medication? The answer, drawn from 37 studies and more than 9,000 participants, was more sobering than most patients or prescribers expected — and it's a conversation every current or prospective GLP-1 user deserves to have before starting, not after stopping.
People who stop GLP-1 medications like Wegovy, Ozempic, Mounjaro, or Zepbound regain weight at roughly 0.8kg (1.8 lb) per month — about four times faster than people who stop diet-and-exercise programmes. At that rate, most people return to their starting weight within approximately 18 months, and the cardiometabolic improvements (blood sugar, cholesterol, blood pressure) reverse on a similar timeline.
This isn't a reason to avoid these medications — for many people, they remain genuinely transformative. It's a reason to plan the "after" phase with the same seriousness as the "during" phase. This guide covers exactly what the research found and what to do about it.
The Oxford Study That Changed the Conversation
The paper, titled "Weight regain following the cessation of medication for weight management," was a systematic review and meta-analysis led by Dimitrios Koutoukidis and colleagues at Oxford, published in The BMJ in January 2026. It pooled data across 37 studies with an average treatment duration of 10 months and average follow-up of 8 months after stopping — making it the largest and most up-to-date analysis of this specific question to date.
The headline finding: people on any weight-loss medication lost an average of 8.3kg during treatment but regained 4.8kg within the first year of stopping, putting them back to their original weight within roughly 1.7 years. For the newer, more potent medications specifically — semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) — the pattern was similar but compressed: people lost just under 15kg during treatment but regained roughly 10kg within the first year, tracking back to baseline in approximately 1.5 years.
How Fast Weight Actually Comes Back
| Group | Average Regain Rate | Projected Time to Baseline |
|---|---|---|
| All weight-loss medications (pooled) | ~0.4 kg/month | ~1.7 years |
| Semaglutide & tirzepatide specifically | ~0.8 kg/month (1.8 lb) | ~1.5 years |
| Diet and exercise programmes (no medication) | ~4x slower than medication | ~4 years |
As Oxford researcher Susan Jebb explained at the study's press briefing, this isn't necessarily a story about the drugs failing — much of the faster percentage regain reflects the fact that people on GLP-1 medications typically lost considerably more weight in the first place. But the underlying mechanism matters regardless of framing: when appetite suppression from the drug ends, the biological and behavioural systems that drove the original weight gain are often still there, unaddressed, waiting.
Why Medication Regain Outpaces Diet-and-Exercise Regain
GLP-1 medications work primarily by suppressing appetite — slowing gastric emptying and signalling fullness to the brain via GLP-1 receptor activation. This mechanism does the work of behaviour change for you, which is precisely why it's so effective during treatment. It's also precisely why regain accelerates once treatment stops: if the underlying eating patterns, activity habits, and food environment weren't also adjusted during treatment, there's little left in place once the appetite suppression is removed.
Diet-and-exercise-based weight loss, by contrast, requires building new habits and behaviours from the start — a slower, harder process, but one that leaves something durable in place once the "programme" phase ends. This is the most plausible explanation for why regain after stopping medication happens roughly four times faster.
It's Not Just the Scale — What Else Reverses
The Oxford analysis also tracked cardiometabolic risk markers, not just body weight, and found that improvements in HbA1c (blood sugar), fasting glucose, cholesterol, triglycerides, and blood pressure achieved during treatment were projected to reverse on a broadly similar timeline to the weight regain itself — within roughly 1.4 years of stopping. This means the health benefits many patients associate with these medications are not necessarily permanent gains locked in by the treatment period alone; they're closely tied to whether the weight loss itself is sustained.
Why People Stop Taking These Medications
Understanding this regain pattern matters practically because stopping is extremely common — researchers at the same Oxford briefing noted that roughly half of people discontinue GLP-1 medications within a year of starting. The most commonly cited reasons include:
- Cost. The majority of GLP-1 users, particularly in the US, pay out of pocket or face significant insurance restrictions, and prices remain a major barrier despite recent negotiated reductions.
- Side effects. Gastrointestinal side effects — nausea, constipation, reflux — are common enough to drive discontinuation for a meaningful subset of users.
- Reaching a goal weight. Some patients stop once they've hit a target, not realising the medication may have been functioning more like ongoing management than a finite course.
Five Evidence-Based Steps to Protect Against Regain
- Build resistance training into the treatment period, not just after it. Muscle mass built or preserved while on the medication provides a metabolic buffer that persists after stopping, unlike appetite suppression itself.
- Hit your protein target throughout treatment. Since appetite is suppressed, deliberately prioritising protein protects against the muscle loss that would otherwise worsen your post-treatment metabolic starting point. The protein intake calculator sets this target precisely.
- Use the treatment window to build sustainable habits, not just lose weight. Meal structure, regular activity, and sleep habits established while appetite is suppressed are far easier to build than trying to establish them for the first time post-treatment, when hunger has returned to baseline.
- Discuss tapering with your prescriber rather than stopping abruptly. While formal evidence on tapering protocols specifically is still developing, many clinicians favour a gradual dose reduction over an abrupt stop to give behavioural adaptations time to take hold.
- Recalculate your maintenance calories before, not after, stopping. Knowing your accurate TDEE at your new, lower weight — via the TDEE calculator — gives you a concrete target to eat toward once appetite suppression fades, rather than navigating the transition blind.
Tapering vs. Stopping Abruptly
The Oxford study itself did not specifically compare tapering protocols against abrupt discontinuation — most included studies involved people stopping treatment outright rather than gradually reducing dose. However, the broader clinical rationale for tapering (used commonly with many other medications that suppress appetite or affect metabolic hormones) is to allow behavioural and physiological systems time to adjust incrementally, rather than facing the full return of baseline appetite all at once. If you're considering stopping, this is worth raising directly with your prescriber rather than deciding independently.
Frequently Asked Questions
Will I definitely regain all the weight if I stop Ozempic or Wegovy?
Not definitely, but the average pattern found in the Oxford analysis shows most people trend back toward their starting weight within roughly 1.5 years without additional support. Individual outcomes vary considerably based on habits built during treatment, ongoing activity levels, and whether structured support continues after stopping.
Why does regain happen faster after stopping medication than after stopping a diet?
GLP-1 medications suppress appetite directly through a biological mechanism, which does much of the "work" of eating less without requiring the same behavioural habit-building that diet-and-exercise approaches necessitate from the start. Once that suppression ends, there's often less of a durable behavioural foundation left in place, unless it was deliberately built during treatment.
Do the health benefits (blood sugar, cholesterol) also disappear after stopping?
The Oxford analysis found that cardiometabolic improvements achieved during treatment were projected to reverse on a broadly similar timeline to the weight itself — roughly 1.4 years. This underscores that these benefits are closely tied to sustained weight loss, not necessarily locked in permanently by the treatment period alone.
Should I just stay on a GLP-1 medication indefinitely to avoid regain?
This is a genuinely individual medical decision that depends on your health profile, access, cost, and how you tolerate the medication long-term — it should be made with your prescriber. Many clinicians now frame these medications more as chronic disease management, similar to blood pressure medication, than as a finite course.
Is it better to taper off slowly or stop suddenly?
The Oxford study didn't directly compare these approaches, but the general clinical rationale favours a gradual taper, discussed with your prescriber, to give behavioural adjustments time to take hold rather than facing a sudden full return of appetite.
What can I do during treatment to reduce my regain risk later?
Prioritising protein intake, maintaining resistance training, and building consistent eating and activity habits during the treatment period — rather than treating it purely as a period of passive weight loss — gives you a stronger foundation once appetite suppression ends.
References & Sources
- Koutoukidis, D. A. et al. (2026). Weight regain following the cessation of medication for weight management: a systematic review and meta-analysis. The BMJ, 392, e083496.
- University of Oxford (2026). New study finds that stopping weight-loss drugs is linked to faster regain than ending diet programmes. Oxford News & Events, January 8, 2026.
- BMJ Group (2026). Stopping weight loss drugs linked to weight regain and reversal of heart health markers.
- Wilding, J. P. H. et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
- MacrosMeasure (2025). Free TDEE Calculator.
- MacrosMeasure (2025). Free Protein Intake Calculator.
Calculate your own numbers — free.
18 science-backed calculators covering everything in this article and more.